Guardant Health(US:GH) Businesswire·2026-01-19 13:05Core Insights - Guardant Health, Inc. has announced a multi-year collaboration with Merck to support the development and commercialization of Merck's oncology portfolio using the Guardant Infinity Smart platform [1] - The collaboration aims to enhance the precision of oncology programs by ensuring that clinical trials have the necessary molecular clarity to identify the right patients for treatment [1] Company Overview - Guardant Health is a leading precision oncology company founded in 2012, focused on improving patient care and accelerating cancer therapies through advanced blood and tissue tests, real-world data, and AI analytics [2] - The company's tests are designed to improve outcomes across all stages of cancer care, including early screening, monitoring for recurrence, and treatment selection for advanced cancer patients [2] Collaboration Details - The collaboration includes using Guardant's portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck's global clinical studies [4] - There will be an evaluation of opportunities to develop novel therapies using Guardant liquid biopsy tests as companion diagnostics [4] - The partnership will also focus on global commercialization of drugs and companion diagnostics in markets including the US, Asia-Pacific, UK, and EU [4]